164 related articles for article (PubMed ID: 27766744)
1. PTTG1 Levels Are Predictive of Saracatinib Sensitivity in Ovarian Cancer Cell Lines.
Nakachi I; Helfrich BA; Spillman MA; Mickler EA; Olson CJ; Rice JL; Coldren CD; Heasley LE; Geraci MW; Stearman RS
Clin Transl Sci; 2016 Dec; 9(6):293-301. PubMed ID: 27766744
[TBL] [Abstract][Full Text] [Related]
2. Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo.
Simpkins F; Hevia-Paez P; Sun J; Ullmer W; Gilbert CA; da Silva T; Pedram A; Levin ER; Reis IM; Rabinovich B; Azzam D; Xu XX; Ince TA; Yang JY; Verhaak RG; Lu Y; Mills GB; Slingerland JM
Clin Cancer Res; 2012 Nov; 18(21):5911-23. PubMed ID: 22896656
[TBL] [Abstract][Full Text] [Related]
3. PAI-1 induces Src inhibitor resistance via CCL5 in HER2-positive breast cancer cells.
Fang H; Jin J; Huang D; Yang F; Guan X
Cancer Sci; 2018 Jun; 109(6):1949-1957. PubMed ID: 29601121
[TBL] [Abstract][Full Text] [Related]
4. Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model.
Yang JC; Bai L; Yap S; Gao AC; Kung HJ; Evans CP
Mol Cancer Ther; 2010 Jun; 9(6):1629-37. PubMed ID: 20484016
[TBL] [Abstract][Full Text] [Related]
5. miR-19b-3p inhibits breast cancer cell proliferation and reverses saracatinib-resistance by regulating PI3K/Akt pathway.
Jin J; Sun Z; Yang F; Tang L; Chen W; Guan X
Arch Biochem Biophys; 2018 May; 645():54-60. PubMed ID: 29550144
[TBL] [Abstract][Full Text] [Related]
6. Gene array and fluorescence in situ hybridization biomarkers of activity of saracatinib (AZD0530), a Src inhibitor, in a preclinical model of colorectal cancer.
Arcaroli JJ; Touban BM; Tan AC; Varella-Garcia M; Powell RW; Eckhardt SG; Elvin P; Gao D; Messersmith WA
Clin Cancer Res; 2010 Aug; 16(16):4165-77. PubMed ID: 20682712
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of Src inhibitor saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas.
Cavalloni G; Peraldo-Neia C; Sarotto I; Gammaitoni L; Migliardi G; Soster M; Marchiò S; Aglietta M; Leone F
Mol Cancer Ther; 2012 Jul; 11(7):1528-38. PubMed ID: 22452946
[TBL] [Abstract][Full Text] [Related]
8. An ovarian cancer model with positive ER: Reversion of ER antagonist resistance by Src blockade.
Li L; Li X; Han X; Yang T; Fu J; Zhang Y; Gou W
Oncol Rep; 2014 Sep; 32(3):943-50. PubMed ID: 24968896
[TBL] [Abstract][Full Text] [Related]
9. The clinical value and biological function of PTTG1 in colorectal cancer.
Ren Q; Jin B
Biomed Pharmacother; 2017 May; 89():108-115. PubMed ID: 28219049
[TBL] [Abstract][Full Text] [Related]
10. Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells.
Simpkins F; Jang K; Yoon H; Hew KE; Kim M; Azzam DJ; Sun J; Zhao D; Ince TA; Liu W; Guo W; Wei Z; Zhang G; Mills GB; Slingerland JM
Clin Cancer Res; 2018 Oct; 24(19):4874-4886. PubMed ID: 29959144
[No Abstract] [Full Text] [Related]
11. Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo.
Chen Y; Alvarez EA; Azzam D; Wander SA; Guggisberg N; Jordà M; Ju Z; Hennessy BT; Slingerland JM
Breast Cancer Res Treat; 2011 Jul; 128(1):69-78. PubMed ID: 20669046
[TBL] [Abstract][Full Text] [Related]
12. Saracatinib impairs the peritoneal dissemination of diffuse-type gastric carcinoma cells resistant to Met and fibroblast growth factor receptor inhibitors.
Yamaguchi H; Takanashi M; Yoshida N; Ito Y; Kamata R; Fukami K; Yanagihara K; Sakai R
Cancer Sci; 2014 May; 105(5):528-36. PubMed ID: 24612061
[TBL] [Abstract][Full Text] [Related]
13. Effects of Src kinase inhibition by saracatinib (AZD0530) on bone turnover in advanced malignancy in a Phase I study.
Hannon RA; Finkelman RD; Clack G; Iacona RB; Rimmer M; Gossiel F; Baselga J; Eastell R
Bone; 2012 Apr; 50(4):885-92. PubMed ID: 22245630
[TBL] [Abstract][Full Text] [Related]
14. Role of the pituitary tumor transforming gene 1 in the progression of hepatocellular carcinoma.
Liang M; Chen X; Liu W; Li S; Li C; Jiang L; Lv S
Cancer Biol Ther; 2011 Feb; 11(3):337-45. PubMed ID: 21099350
[TBL] [Abstract][Full Text] [Related]
15. RNAi-mediated knockdown of pituitary tumor- transforming gene-1 (PTTG1) suppresses the proliferation and invasive potential of PC3 human prostate cancer cells.
Huang SQ; Liao QJ; Wang XW; Xin DQ; Chen SX; Wu QJ; Ye G
Braz J Med Biol Res; 2012 Nov; 45(11):995-1001. PubMed ID: 22872288
[TBL] [Abstract][Full Text] [Related]
16. Pituitary tumor transforming gene-1 in non-small cell lung cancer: Clinicopathological and immunohistochemical analysis.
Wang F; Liu Y; Chen Y
Biomed Pharmacother; 2016 Dec; 84():1595-1600. PubMed ID: 27829547
[TBL] [Abstract][Full Text] [Related]
17. Common PIK3CA mutants and a novel 3' UTR mutation are associated with increased sensitivity to saracatinib.
Arcaroli JJ; Quackenbush KS; Powell RW; Pitts TM; Spreafico A; Varella-Garcia M; Bemis L; Tan AC; Reinemann JM; Touban BM; Dasari A; Eckhardt SG; Messersmith WA
Clin Cancer Res; 2012 May; 18(9):2704-14. PubMed ID: 22553375
[TBL] [Abstract][Full Text] [Related]
18. GDNF induces RET-SRC-HER2-dependent growth in trastuzumab-sensitive but SRC-independent growth in resistant breast tumor cells.
Gardaneh M; Shojaei S; Kaviani A; Behnam B
Breast Cancer Res Treat; 2017 Apr; 162(2):231-241. PubMed ID: 28116540
[TBL] [Abstract][Full Text] [Related]
19. Pituitary tumor-transforming gene-1 serves as an independent prognostic biomarker for gastric cancer.
Xu MD; Dong L; Qi P; Weng WW; Shen XH; Ni SJ; Huang D; Tan C; Sheng WQ; Zhou XY; Du X
Gastric Cancer; 2016 Jan; 19(1):107-15. PubMed ID: 25627474
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration.
Bai L; Yang JC; Ok JH; Mack PC; Kung HJ; Evans CP
Int J Cancer; 2012 Jun; 130(11):2693-702. PubMed ID: 21792888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]